A Survey of the Relationship between Serum Testosterone Level and Expressions of Androgen, Progesterone and Estrogen Receptors and HER2 in Iranian Women with Breast Cancer (original) (raw)
Related papers
International Archives of BioMedical and Clinical Research, 2017
Background: Breast cancer is the second most common malignancy in Indian women. Among the members of the steroid receptor superfamily the role of estrogen and progesterone receptors (ER and PR) is well established in breast cancer in predicting the prognosis and management of therapy, however, little is known about the clinical significance of androgen receptor (AR) in breast carcinogenesis. The present study was aimed to evaluate the expression of AR in breast cancer and to elucidate its clinical significance by correlating it with other hormonal receptors and clinical parameters. Methods: It was a prospective study which include 30 patients of histopathologically proven breast cancer admitted to department of surgery at S.N Medical College Agra .Expression of AR, ER, PR, HER2/ neu receptor by immunohistochemistry (IHC) and clinical parameters were studied. Results: AR expression is related to ER(P<0.015), PR(p<0.008) and triple negative breast cancer patients (p <0.008). There is significant correlation between AR and menopausal status(p<0.006) while no significant correlation was found with age and parity. Conclusions: Since there is significant association of AR in triple negative and post-menopausal women so we can say that AR expression possibly help in confirming their predictive role for therapeutic response in breast cancer patients
Journal of the Egyptian National Cancer Institute, 2012
Although Breast carcinoma had many targeted biomarkers for its treatment, however, it is a heterogeneous disease with different outcomes and need new markers especially for the triple negative group when estrogen receptor, progesterone receptors and Her2/neu are negative. Androgen receptor is a new target with unclear role. The aim of this study was to examine the prevalence of androgen receptors in invasive breast cancer and tries to elucidate its relation to some well recognized clinicopathological and immunohistochemical markers. One hundred and fifty cases of invasive breast carcinoma were evaluated for type, grade and stage and studied immunohistochemically for estrogen receptor, progesterone receptor, Her2/neu and androgen expression. Androgen receptor expression was correlated with histopathological factors and the three studied markers separately then the studied cases were classified into three groups according to estrogen, progesterone receptor and Her2/neu expression and ...
Testosterone and Biological Characteristics of Breast Cancers in Postmenopausal Women
Cancer Epidemiology Biomarkers & Prevention, 2009
Androgens are involved in the development of breast cancer, although the mechanisms remain unclear. To further investigate androgens in breast cancer, we examined the relations between serum testosterone and age, body mass index (BMI), tumor size, histologic type, grade, axillary node involvement, estrogen receptor status, progesterone receptor status, and HER2 overexpression in a cross-sectional study of 592 postmenopausal breast cancer patients. Mean testosterone differences according to categories of patient and tumor characteristics were assayed by Fisher's or Kruskall-Wallis test as appropriate; adjusted odds ratios (OR) of having a tumor characteristic by testosterone tertiles were estimated by logistic regression. Testosterone concentrations were significantly higher in women with BMI ≥30 versus BMI <25. ORs of having a tumor ≥2 cm increased significantly with increasing testosterone tertiles, and the association was stronger in women ≥65 years. The OR of having infiltrating ductal carcinoma was significantly higher in the highest compared with the lowest testosterone tertile. ORs of having estrogen receptorand progesterone receptor-negative versus estrogen receptor-and progesterone receptor-positive tumors decreased significantly with increasing testosterone tertiles. In women ≥70 years, those with high testosterone had a significantly greater OR of HER2-negative cancer than those with low testosterone. These results support previous findings that high-circulating testosterone is a marker of hormone-dependent breast cancer. The agerelated differences in the association of testosterone with other disease and patient characteristics suggest that breast cancers in older postmenopausal women differ markedly from those in younger postmenopausal women. The relationship between testosterone and HER2 status in the oldest patients merits further investigation. (Cancer Epidemiol Biomarkers Prev
Ibnosina Journal of Medicine and Biomedical Sciences, 2016
Background: Breast cancer has a tremendous heterogeneity in its clinical behavior. The objective of this study is to assess the positive expression of estrogen receptors (ER), progesterone receptors (PR) and HER2 overexpression in relationship to the age of patients, and certain prognostic parameters such as tumor grade, size and lymph node involvement. Patients and methods: A cross sectional case study was conducted between June 2011 and June 2014 at the pathology department of Rizgary General Hospital, Erbil, Iraq. 114 Confirmed cases of breast cancer were studied. Immunohistochemistry was used to evaluate the expression of ER, PR and HER2 status. Patients'f mean age was 48±5 (Range: 28-83) years; 57% of them were ≥50 years. Results: The expression of ER and PR was 58.8% and 49.1% respectively. HER2 overexpression (score +3) was 29.8%. Hormone receptors (ER and PR) correlated significantly with age and grade of the tumor whereas HER2 overexpression correlated significantly wit...
Serum testosterone levels and breast cancer recurrence
International Journal of Cancer, 2004
Prospective studies show that high serum levels of androgens and estrogens are associated with increased incidence of postmenopausal breast cancer. The aim of the present analysis was to study the prognostic value of serum testosterone, estradiol and related factors in postmenopausal breast cancer patients. One hundred and ten patients without clinical recurrence were included in the study. After 5.5 years of follow-up, 31 patients developed distant metastasis (16), local relapse (4), or contralateral breast cancer (11). The risk of adverse events in relation to hormone level was examined by Cox' proportional hazard modeling, adjusting for hormone receptor status and stage at diagnosis. Body mass index and serum levels of testosterone, estradiol and glucose were significantly higher in patients who recurred than those who did not. The hazard ratios were 1.8 (95% CI ؍ 0.5-6.3) for the middle and 7.2 (95% CI ؍ 2.4-21.4) for the upper tertiles of baseline testosterone distribution. Other hormones had only minor influence on prognosis. High testosterone predicts breast cancer recurrence. Further studies are required to determine whether dietary or other medical intervention to reduce testosterone can reduce the recurrence of breast cancer.
2016
Carcinoma of the breast is the most common malignant tumor and the most common cause of death from carcinoma in females all over the world. In recent years, interest in prognostic factors has been stimulated by the success of systemic adjuvant therapy for early stage of breast carcinoma. The important pathological prognostic factors in invasive breast carcinoma include patient's age, tumor size, lymph node metastasis, nuclear grade, histological grade, histological type, hormone receptor status & HER2/neu. Tumors that express both Estrogen Receptor(ER) and Progesterone Receptor(PR) have the greatest benefit from hormonal therapy. HER2/neu has its role as a prognostic indicator and as a predictor of response to Trastuzumab (Herceptin) therapy in breast cancer patients. The study was conducted in. 73 cases of mastectomy specimens were received and clinical staging, histological grading and NPI score were analysed for these cases. 55 cases were selected at random and ER, PR & HER2/neu status was analysed. Greater than 80% of the cases were 40 years and above and majority (56.2%) were postmenopausal. Maximum number of cases (65.8%) were stage 2 and grade 2(72.6%). ER was positive in 30.9%, PR in 25.5%, HER2/neu in 30.9%. The prevalence of hormone receptor positivity was less & HER2/neu positivity was higher which was in concordance with the studies conducted in Asian population compared with western world. There was a statistically significant association between the two hormone receptor expressions but not with other prognostic factors.
Proliferative activity and steroid hormone receptor status in male breast carcinoma
The Journal of Steroid Biochemistry and Molecular Biology, 1998
Hormonal factors have been implicated in the development of both female and male breast cancers (MBC). However, MiBCs are rare and seem to have different biological behavior than those of females. The aim of this study was to evaluate proliferative activity and to establish an association with steroid hormone: receptor concentration and clinicopathological parameters in MBC. Proliferative activity was assessed in 18 MBC by mitotic figure counts and immunohistochemical evaluation of MIB-1 and prolit~erating cell nuclear antigen (PCNA). Estrogen (ER), progesterone (PR) and androgen (AR) receptors were evaluated in serial section from the same tumor by immunohistochemistry. PCNA (range 17-73%; mean, 51.6%) and MIB-1 (range 18.5-58%; mean 38.4%) were positive correlated with the mitotic rate. High proliferative activity assessed either by mitotic index or MIB-1 expression was associated with more poorly differentiated tumors. Sixty one percent (11/ 18) of the tumors were ER+, 72% (13/18) PR+ and 38.5% (5113) AR+. Proliferative activity in tumors displaying ER+ IPR+ phenotype showed a tendency to be higher than in ER-/PR-tumors. This difference was statistically significant when MIB-1 expression was used as proliferation marker. An association between AR concentration and age at diagnosis was found; in the AR negative group (8113) mean ~ge at diagnosis was 54.4 ± 7.3 which was significantly lower than the age of patients with AR+ tumors, 63.2 ± 11.1 (5113). Results presented here show that decreased androgen action (AR-) within the breast might contribute to an earlier development of MBC. Besides that, the presence of ER and PR in carcinoma cells is considered to provide a growth advantage as shown by the positive association between the phenotype (ER+ IPR+) and high proliferative activity. These results add information for a better understanding of hormonal control of MBC growth and development.